Avanir Targets Impax Over Generic Nuedexta Plans

Law360, New York (October 9, 2012, 1:38 PM EDT) -- Avanir Pharmaceuticals Inc. on Monday sued rival Impax Laboratories Inc. in Delaware federal court, claiming Impax's plans to make a generic version of involuntary-emotion drug Nuedexta infringe one of its patents.

According to Aliso Viejo, Calif.-based Avanir’s complaint, Impax’s plans to make a generic version of Nuedexta — a combination of the drugs dextromethorphan and quinidine, used to treat a neurological condition involving involuntary laughing or crying episodes — infringes U.S. Patent Number 8,227,484, one of several patents covering the drug.

“Avanir will be substantially and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.